Liu X-Q, Zhuang M, Wang Z, Huber R M
Department of Medical Oncology, No. 1 Renmin Hospital of Lianyungang, Lianyungang, P.R. China.
Eur Rev Med Pharmacol Sci. 2014;18(18):2772-6.
At present, fluoropyrimidine, based on 5-fluorouracil (5-FU), remains one of the most frequently prescribed chemotherapeutics drugs for the treatment of cancer. Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme in the catabolism of 5-FU, and DPD enzymatic activities are usually varied dramatically from individual to individual, including both the intrapatient differences and the interpatient variability. There is a certain correlation between the DPD activity and efficacy and toxicity following the administration of fluoropyrimidine drugs. Partial or complete loss of DPD activity can lead to serious or even lethal toxicity. In this article, we review the relationship between DPD activity and efficacy and toxicity following the administration of fluoropyrimidine drugs, and also the structure, function, and characteristics of DPD. We report here that measurement of DPD activity may become a strategy and be paid much attention to predict the efficacy and toxicity prior to starting a fluoropyrimidine-based therapy.
目前，以5-氟尿嘧啶（5-FU）为基础的氟嘧啶仍然是治疗癌症最常用的化疗药物之一。二氢嘧啶脱氢酶（DPD）是5-FU分解代谢的限速酶，DPD酶活性在个体之间通常有很大差异，包括患者体内差异和患者间变异性。氟嘧啶类药物给药后，DPD活性与疗效和毒性之间存在一定的相关性。DPD活性部分或完全丧失可导致严重甚至致命的毒性。在本文中，我们综述了氟嘧啶类药物给药后DPD活性与疗效和毒性之间的关系，以及DPD的结构、功能和特性。我们在此报告，测定DPD活性可能成为一种策略，并在开始基于氟嘧啶的治疗之前预测疗效和毒性方面受到高度重视。
